Institut de Recherche en Cancérologie de Montpellier INSERM U1194, Univ Montpellier, Inserm, ICM, CNRS, Campus Val d'Aurelle 208 avenue des Apothicaires, 34298, Montpellier cedex 5, France.
UNICANCER R&D, Paris, France.
Sci Rep. 2023 Feb 15;13(1):2739. doi: 10.1038/s41598-023-29948-4.
Optimizing the biomarker combination to be analyzed in liquid biopsies should improve personalized medicine. We developed a method to purify circulating cell-free mRNAs from plasma samples and to quantify them by RT-qPCR. We selected three candidate colorectal cancer biomarkers (B2M, TIMP-1, and CLU). Their mRNA levels were significantly higher in plasma of patients with metastatic colorectal cancer patients (mCRC) (n = 107) than in healthy individuals (HI) (n = 53). To increase the discriminating performance of our method, we analyzed the sum of the three mRNA levels (BTC index). The area under the ROC curve (AUC) to estimate the BTC index capacity to discriminate between mCRC and HI plasma was 0.903. We also determined the optimal BTC index cut-off to distinguish between plasma samples, with 82% of sensitivity and 93% of specificity. By using mRNA as a novel liquid biopsy analytical parameter, our method has the potential to facilitate rapid screening of CRCm.
优化用于分析液体活检的生物标志物组合应该可以改善个性化医疗。我们开发了一种从血浆样本中纯化循环无细胞 mRNA 并通过 RT-qPCR 定量的方法。我们选择了三种候选结直肠癌生物标志物（B2M、TIMP-1 和 CLU）。在转移性结直肠癌患者（mCRC）（n=107）的血浆中，其 mRNA 水平明显高于健康个体（HI）（n=53）。为了提高我们方法的区分性能，我们分析了三种 mRNA 水平的总和（BTC 指数）。BTC 指数区分 mCRC 和 HI 血浆的能力的 ROC 曲线下面积（AUC）为 0.903。我们还确定了区分血浆样本的最佳 BTC 指数截断值，其灵敏度为 82%，特异性为 93%。通过使用 mRNA 作为新型液体活检分析参数，我们的方法有可能促进 CRCm 的快速筛查。
